Lysosomal dysfunction, cellular pathology and clinical symptoms: Basic principles

Acta Paediatrica, International Journal of Paediatrics

Volumn 95, Issue SUPPL. 451, 2006, Pages 77-82

  Reuser, Arnold J J ^a   Drost, Maarten R ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Cellular pathology; Lysosomal storage disorders; Pompe disease

Indexed keywords

ALPHA GLUCOSIDASE; BETA GALACTOSIDASE; DESMIN; DYSTROPHIN; GLUCOSYLCERAMIDE; LYSOSOME ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BETA GALACTOSIDOSIS; CELL INCLUSION; CELL TYPE; CONFERENCE PAPER; ENZYME DEFICIENCY; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; KUPFFER CELL; LIVER; LYSOSOME; LYSOSOME STORAGE DISEASE; MOUSE; MUCOPOLYSACCHARIDOSIS; MUSCLE WEAKNESS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SKELETAL MUSCLE; SYMPTOMATOLOGY; TISSUE INJURY;

ANIMALS; BETA-GALACTOSIDASE; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; LIVER; LYSOSOMAL STORAGE DISEASES; LYSOSOMES; MACROPHAGES; MUCOPOLYSACCHARIDOSES; MUSCLE CONTRACTION; MUSCLE, SKELETAL; MYOFIBRILS; SARCOMERES;

EID: 33646714143     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1080/08035320600618957     Document Type: Conference Paper

References (21)

1. Beutler E, Grabowski G. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th edn. New York: McGraw-Hill; 2001. p. 3635-68.
2. Sidransky E, Sherer DM, Ginns EI. Gaucher disease in the neonate: a distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene. Pediatr Res 1992;32:494-8.
3. Banker BQ, Miller JQ, Crocker AC. The neurological disorder in infantile Gaucher's disease. Trans Assoc Am Physicians 1961;86:43-8.
4. Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem 1982;39:709-18.
5. Tran HA. Erlenmeyer flask. J Clin Endocrinol Metab 2004;89:4827-8.
6. Neufeld EF, Muenzer J. The Mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th edn. New York: McGraw-Hill; 2001. p. 3421-52.
7. Suzuki Y, Oshima A, Nanba E. GM1-Gangliosidosis and Morquio B disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th edn. New York: McGraw-Hill; 2001. p. 3775-809.
8. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-9.
9. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004; 144:581-8.
10. Harmatz P, Whitley CB, Waber L, Pais R, Steiner R, Plecko B, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004;144:574-80.
11. Schiffmann R, Kopp JB, Austin HA, 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.
12. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
13. Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005;128:671-7.
14. Van den Hout HM, Hop W, Van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332-40.
15. Hesselink RP, Van Kranenburg G, Wagenmakers AJ, Van der Vusse GJ, Drost MR. Age-related decline in muscle strength and power output in acid 1-4 alpha-glucosidase knockout mice. Muscle Nerve 2005;31:374-81.
16. Morgan DL, Proske U. Popping sarcomere hypothesis explains stretch-induced muscle damage. Clin Exp Pharmacol Physiol 2004;31:541-5.
17. Monti RJ, Roy RR, Hodgson JA, Edgerton VR. Transmission of forces within mammalian skeletal muscles. J Biomech 1999;32:371-80.
18. Hesselink RP, Gorselink M, Schaart G, Wagenmakers AJ, Kamphoven J, Reuser AJ, et al. Impaired performance of skeletal muscle in alpha-glucosidase knockout mice. Muscle Nerve 2002;25:873-83.
19. Drost MR, Hesselink RP, Oomens CW, van der Vusse GJ. Effects of non-contractile inclusions on mechanical performance of skeletal muscle. J Biomech 2005;38:1035-43.
20. Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004;113:e448-57.
21. Winkel LP, Van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF, et al. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 2004;55:495-502.